202 related articles for article (PubMed ID: 38068251)
1. Oligometastatic Prostate Cancer-The Middle Child Syndrome.
Lim EJ; Su M; Saiduzzaman BM; Tay KJ; Ho HSS; Tokas T; Somani BK; Gauhar V; Yuen JSP; Chen K
J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068251
[TBL] [Abstract][Full Text] [Related]
2. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.
Alberto M; Yim A; Papa N; Siva S; Ischia J; Touijer K; Eastham JA; Bolton D; Perera M
Front Oncol; 2022; 12():929444. PubMed ID: 36059632
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO).
Rogowski P; Trapp C; von Bestenbostel R; Konnerth D; Marschner S; Schmidt Hegemann NS; Belka C; Li M
Strahlenther Onkol; 2022 Aug; 198(8):727-734. PubMed ID: 35364690
[TBL] [Abstract][Full Text] [Related]
5. Comparison of
Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
7. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
Lanfranchi F; Belgioia L; Marcenaro M; Zanardi E; Timon G; Riondato M; Giasotto V; Zawaideh JP; Tomasello L; Mantica G; Piol N; Borghesi M; Traverso P; Satragno C; Panarello D; Scaffidi C; Romagnoli A; Rebuzzi SE; Coco A; Spina B; Morbelli S; Sambuceti G; Terrone C; Barra S; Fornarini G; Bauckneht M
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612319
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
13. Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches.
Dorff TB; Kasparian S; Garg N; Liu S; Pal SK; Wong J; Dandapani S
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902798
[TBL] [Abstract][Full Text] [Related]
14. Role of Metastasis-Directed Therapy in Genitourinary Cancers.
Lee KN; Huynh MA
Curr Treat Options Oncol; 2024 May; 25(5):605-616. PubMed ID: 38573430
[TBL] [Abstract][Full Text] [Related]
15. Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches.
Oka R; Utsumi T; Noro T; Suzuki Y; Iijima S; Sugizaki Y; Somoto T; Kato S; Endo T; Kamiya N; Suzuki H
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339259
[TBL] [Abstract][Full Text] [Related]
16. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
17. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
18.
Udovicich C; Perera M; Hofman MS; Siva S; Del Rio A; Murphy DG; Lawrentschuk N
Prostate Int; 2017 Dec; 5(4):125-129. PubMed ID: 29188197
[TBL] [Abstract][Full Text] [Related]
19. Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.
Müller PJ; Dietlein M; Kobe C; Heidenreich A; Drzezga A
Nuklearmedizin; 2022 Aug; 61(4):314-324. PubMed ID: 35388442
[TBL] [Abstract][Full Text] [Related]
20. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
